Springworks Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Springworks Therapeutics (US): 3 reconciled FDA prescription therapies, $39.9M 2024 CMS Part D & Medicaid spend, and $34,650 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2043-01-01
2024 CMS Total Public Spend$39.9M
2024 Medicare Part D Spend$20.0M
2024 Medicaid Spend$19.9M
California HCAI SB 17 FilingsSpecialty launch notice ($34,650 intro WAC)